Want to see GB:SPI full AI Analyst Report?
Spire Healthcare (SPI) AI Stock Analysis
Top Page
Spire Healthcare
(LSE:SPI)
The overall score is driven primarily by solid operational performance and cash generation, but is held back by high leverage and weak net-income conversion. Technicals add support via a clear uptrend, while valuation is the main downside due to a high P/E and low dividend yield.
Spire Healthcare (SPI) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 997.49M
- Dividend Yield
- 0.60%
- Average Volume (3M)
- 2.49M
- Price to Earnings (P/E)
- -529.8
- Beta (1Y)
- 0.55
- Revenue Growth
- 1.97%
- EPS Growth
- -110.22%
- Country
- UK
- Employees
- 17,800
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Spire Healthcare Business Overview & Revenue Model
Company Description
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics in the United Kingdom. It operates in two segments: Hospitals Business and Primary Care. The company provides diagnostics, inpatient, day case...
How the Company Makes Money
Spire Healthcare makes money primarily by charging for healthcare services delivered through its hospitals and clinics. Key revenue streams typically include: (1) Private patient revenue: fees paid by self-paying patients and by private medical insur...
Spire Healthcare Financial Statement Overview
Summary
Strong revenue growth since 2020 and consistently positive operating/free cash flow support the score. However, very thin net margins and elevated leverage (debt well above equity) reduce resilience and dampen returns, keeping the financial profile only moderately strong overall.
Income Statement
66PositiveBalance Sheet
54NeutralCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.58B | 1.58B | 1.51B | 1.36B | 1.20B | 1.11B |
| Gross Profit | 591.40M | 599.10M | 683.60M | 520.60M | 440.50M | 394.10M |
| EBITDA | 241.20M | 265.70M | 250.40M | 231.20M | 193.30M | 182.20M |
| Net Income | -1.90M | 16.40M | 25.40M | 27.30M | 8.60M | -9.70M |
Balance Sheet | ||||||
| Total Assets | 2.35B | 2.38B | 2.34B | 2.29B | 2.16B | 2.24B |
| Cash, Cash Equivalents and Short-Term Investments | 29.80M | 34.70M | 43.70M | 49.60M | 74.20M | 202.60M |
| Total Debt | 1.31B | 1.32B | 1.28B | 1.26B | 1.19B | 1.27B |
| Total Liabilities | 1.63B | 1.63B | 1.60B | 1.55B | 1.43B | 1.53B |
| Stockholders Equity | 725.60M | 742.80M | 748.40M | 739.90M | 731.00M | 709.60M |
Cash Flow | ||||||
| Free Cash Flow | 156.00M | 143.00M | 123.60M | 115.50M | 72.80M | 101.30M |
| Operating Cash Flow | 217.40M | 219.30M | 235.70M | 199.90M | 160.50M | 170.60M |
| Investing Cash Flow | -68.20M | -90.40M | -99.00M | -157.20M | -98.00M | -48.30M |
| Financing Cash Flow | -140.20M | -135.40M | -145.10M | -82.90M | -190.90M | -26.00M |
Spire Healthcare Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SPI, the sentiment is Positive. The current price of 249.00 is above the 20-day moving average (MA) of 247.60, above the 50-day MA of 244.67, and above the 200-day MA of 209.46, indicating a bullish trend. The MACD of 1.16 indicates Positive momentum. The RSI at 72.07 is Negative, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SPI.
Spire Healthcare Peers Comparison
Overall Rating
GB:NIOX68Neutral- GB:SPI64Neutral
GB:CRW60Neutral
GB:OPT56Neutral
GB:PRTC50Neutral
GB:AGY42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:NIOX | 68Neutral | GBP 273.94M | 40.48 | 10.01% | 2.29% | 3.26% | 32.54% |
| GB:SPI | 64Neutral | GBP 1.00B | -529.79 | -0.26% | 0.60% | 1.97% | -110.22% |
| GB:CRW | 60Neutral | GBP 356.58M | 25.05 | 5.94% | 3.20% | -3.45% | -1.68% |
| GB:OPT | 56Neutral | GBP 269.22M | 156.65 | 0.83% | ― | 14.84% | -15.14% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:PRTC | 50Neutral | GBP 287.84M | 157.16 | 0.14% | ― | -4.11% | -96.92% |
| GB:AGY | 42Neutral | GBP 253.30M | -4.04 | 409.00% | ― | 2.94% | -32.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:SPI | Spire Healthcare | 249.00 | 17.58 | 7.60% | |
| GB:AGY | Allergy Therapeutics | 4.00 | -4.90 | -55.06% | |
| GB:NIOX | Circassia Pharmaceuticals | 67.60 | 1.31 | 1.98% | |
| GB:CRW | Craneware Plc | 1048.00 | -1159.15 | -52.52% | |
| GB:PRTC | PureTech Health | 117.40 | -12.40 | -9.55% | |
| GB:OPT | Optima Health PLC | 247.50 | 46.03 | 22.85% |
Spire Healthcare Corporate Events
Spire Healthcare extends Toscafund bid deadline as financing nears completion
NeutralSpire Healthcare has confirmed that funds advised by Toscafund Asset Management, its second-largest shareholder, are continuing to work towards a possible recommended cash offer of 250 pence per share for the entire company, including an option for s...
Spire Healthcare Sets Date for Interim Results Update
NeutralSpire Healthcare Group plc, a major independent healthcare provider in the UK with a broad network of hospitals, clinics and workplace health services, continues to leverage its FTSE 250 status and leading position in orthopaedics and NHS talking the...
Spire Healthcare Names Debbie White as Chair-Designate in Planned Leadership Transition
PositiveSpire Healthcare has announced a planned change in board leadership, with current Chair Sir Ian Cheshire set to step down by no later than 30 September 2026, and senior independent director Debbie White appointed Chair-Designate with immediate effect...
Spire Healthcare grants Toscafund more time on potential £2.50-a-share bid
PositiveSpire Healthcare said funds advised by Toscafund Asset Management, its second-largest shareholder, continue to explore a possible 250 pence per share cash offer for the entire issued and to be issued share capital, with an optional unlisted rollover...
Spire Healthcare Grants Toscafund More Time on Potential Takeover Bid
NeutralSpire Healthcare has disclosed that discussions with Toscafund Asset Management, its second-largest shareholder, over a possible 250 pence-per-share cash takeover remain ongoing, prompting a further extension of the regulatory deadline. Toscafund now...
Spire Healthcare Wins Takeover Deadline Extension as Toscafund Weighs 250p Bid
NeutralSpire Healthcare has secured an extension to the regulatory deadline for Toscafund Asset Management to decide on a possible takeover offer, giving the prospective bidder until 25 June 2026 to announce a firm cash bid at 250 pence per share or walk aw...
Spire Healthcare executives boost shareholdings after exercising incentive awards
PositiveSpire Healthcare has disclosed that its chief executive, Justin Ash, and chief financial officer, Harbant Samra, have exercised vested share awards under the group’s long-term incentive and deferred bonus schemes. After settling tax obligations...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026